Table II.
Nanoparticulate Formulations for Mitoxantrone in Preclinical and Clinical Investigation
| Formulation | Composition | Indication(s) | Development Stage | Ref. |
|---|---|---|---|---|
| Liposome complexed mitoxantrone (LCM) | Soy phosphatidyl choline, cholesterol, phosphatidic acid, D,L-α-tocopherol | Breast cancer | I/II | (136,137) |
| ∆pH Mitoxantrone liposomes | Soy phosphatidyl choline, cholesterol, DPPE-PEG2000 | Leukemia | Preclinical | (138) |
| DSPC/Chol liposomes | DSPC, cholesterol | Leukemia | Preclinical | (139) |
| DMPC/Chol liposomes | DMPC, cholesterol | Leukemia, squamous cell carcinoma, colorectal cancer | Preclinical | (140,141) |
| Liposome-entrapped mitoxantrone Easy-To-Use (LEM-ETU) | DOPC, cholesterol, cardiolipin, alphatocopheryl acid succinate | Various cancers | I | (142,143) |
|
Pegylated liposomal mitoxantrone 60 nm (PLM-60) |
HSPC, cholesterol, DSPE-PEG2000 |
Leukemia, prostate cancer, non-Hodgkin’s lymphoma, various solid tumours, peripheral T cell lymphoma | I/II | (144–146) |
| Mitoxantrone polybutyl cyanacrylate (PBCA) nanoparticles | Butyl cyanacrylate, dextran-70, poloxamer 188 | Leukemia, melanoma | Preclinical | (147,148) |
| Mitoxantrone polybutyl cyanacrylate nanoparticles (DHAQ-PBCA-NP) |
Butyl cyanacrylate, dextran-70, sodium dithionite, sodium chloride |
Hepatocellular carcinoma | II | (149–151) |
| Mitoxantrone solid lipid nanoparticles (MTO-SLN) | Lecithin, Compritol-888, surfactant S-40 | Breast cancer | Preclinical | (152) |
| Mitoxantrone bovine serum albumin nanoparticles (MTO-BSANP) | Bovine serum albumin, glutaraldehyde, folic acid | Ovarian cancer | Preclinical | (153) |
| Mitroxantrone iron oxide magnetic nanoparticles | Iron oxide, dextran | Rhabdomyosarcoma | Preclinical | (154) |